HRS 7415
Alternative Names: HRS-7415Latest Information Update: 04 Dec 2023
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antineoplastics
- Mechanism of Action Protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 01 Dec 2023 Phase-I clinical trials in Solid tumours (Late-stage disease) (PO), prior to December 2023 (Jiangsu HengRui Medicine, December 2023)
- 15 Apr 2022 Jiangsu HengRui Medicine plans a phase I trial for Cancer (Late-stage disease, Metastatic disease) in April 2022 (PO) (NCT05318833)
- 08 Apr 2022 Preclinical trials in Cancer in China before April 2022 (PO)